Back

prof. dr. L.J. Bont

prof. dr. L.J. Bont

Full Professor
prof. dr. L.J. Bont
  • Center for Translational Immunology (CTI) Research
  • Infectious Diseases Research 2

Biography

Biography

Louis Bont is a Paediatrician Infectiologist at the Wilhelmina Children’s Hospital in the University Medical Center Utrecht, The Netherlands. He leads the Utrecht RSV Research Group. He is the coordinator of the Interest Group on Respiratory Infections of the European Society of Pediatric Infectious Diseases (ESPID) Research Committee. Dr. Bont is the founder and chairman of ReSViNET, an international RSV Research consortium. He has a strong interest in education of young talented researchers and founded the successful Training of Upcoming Leaders in Pediatric Science (TULIPS) career training program in the Netherlands. Dr. Bont served as advisor of the World Health Organization (WHO), the European Center of Disease Control (ECDC) and the Europarliament.

Louis Bont did his medical training at the Academic Medical Center in Amsterdam (1989-1996). He performed his PhD under the supervision of professor Jan Kimpen and professor Cobi Heijnen at the Wilhelmina Children’s Hospital (1997-2000). He was a post-doc at the Garofalo lab in Galveston, Texas (2000-2001). After returning to Utrecht, he followed the pediatric residency program followed by a pediatric infectious diseases and immunology fellowship. He have led the RSV Research Group since 2003 and became full professor in 2015.

The vision of his research is to combine clinical and basic research to decrease the global burden of RSV infection. The mission of his research group is to improve knowledge of RSV epidemiology, and to develop safe and effective therapeutic and preventive interventions.

In his work collaborate with patients is of highest importance. His work is supported by the RSV Patient Advisory Board (PAB) since 2012. The PAB has reviewed every grant application by the RSV Research Group. PAB members have been interviewed for newspapers and national television on RSV-related subjects.

Louis Bont actively participates as a teacher in the SUMMA program. In addition, he founded the TULIPS program in 2008 to train colleagues and young clinician-scientists.

Since April 1st 2021, Louis has been given a new position as medical scientific division manager of the Children's Division of the Wilhelmina Children's Hospital in Utrecht.

Side Activities

Sideactivities. Payment are always to UMC Utrecht

A. related to RSV infection

Advisory boards, consultancy and steering committees

  • GlaxoSmithKline, Advisory Board (from 2020 onwards), (>€2200.-)
  • Janssen, Global virtual advisory board, (from 2021 onwards), (>€2200.-)
  • Julius Clinical, Advisor research, (from 2021 onwards) (>€2200.-)
  • AstraZeneca, (2019 onward), (>€2200)
  • MSD, Advisory Board, (from 2020 onwards) (>€2200.-)
  • Pfizer (from 2021 onwards), (>€2200.-)
  • Sanofi (from 2020 onwards), (>€2200.-)
  • ESCMID, member executive committee member ESCMID Study Group for Respiratory viruses (from 2022 onwards), (no payment)

Meetings, speaker’s fees, chairing

  • AstraZeneca, (2021 onwards, >€2200.-)        
  • AstraZeneca, Global Synagis filmed interview, (2021), (<€2200.-)
  • GlaxoSmithKline, Virtual meeting, Consultancy, (2021), (<€2200.-)
  • Janssen, speaker (2021), (<€2200.-)
  • Merck Sharp & Dome, Speaker, (2021), (<€2200.-)
  • Merck Sharp & Dome, RSV Passive Approaches and Niche SIE, (2021), (<€2200.-)
  • Merck Sharp & Dome, RSV Airways Hyper-reactivity and Asthma, (2021), (<€2200.-) 
  • Merck Sharp & Dome, (Teleconference) Meetings SAC, (2020-2021), (<€2200.-)
  • Sanofi, RSV Medical Education Meeting with experts, (2021), (<€2200.-) 
  • Sanofi, ReSiNET Symposium, (2021), (>€2200.-)

B. Sideactivities not related to RSV infection

  • AstraZeneca,  Consultant asthma, (2021), (<€2200.-)
  • GSK, Data Safety Monitoring Board VZV vaccine, (2020) (>€2200.-)
  • MediRisk, Expert Consultancy/Advisory, (2019), (<€2200.-)
  • MeMed, Review KOL report, (2021) (>€2200.-)
  • ESGREV executive committee (2022), (no payment)

 

Potential Conflicts of Interest

Dr. Bont has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (>€100,000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, AstraZeneca, Sanofi, Janssen, Pfizer, MSD and MeMed Diagnostics. UMCU has received major funding for the RSV GOLD study from the Bill and Melinda Gates Foundation. UMCU has received major funding as part of the public private partnership IMI-funded RESCEU and PROMISE projects with partners GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in clinical studies sponsored by MedImmune and Pfizer. UMCU received minor funding (€1,000-25,000 per industrial partner) for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, GSK, Novavax, Pfizer, Moderna, Astrazeneca, MSD, Sanofi, Genzyme, Janssen. Dr. Bont is the founding chairman of the ReSViNET Foundation.

Since April 1st 2021, Louis has been given a new position as medical scientific division manager of the Children's Division of the Wilhelmina Children's Hospital in Utrecht.

Fellowship and Awards

Full Professor (“Stimuleringshoogleraarschap”), expected in May 2015

International Congress of Pediatric Pulmunology (CIPP) Award for Contribution to Understanding Childhood Respiratory Disease and Global Medical Education (2013)

Dirkzwager-Assink Fonds Award by Catharijne Stichting for research on RSV bronchiolitis (2010)

Ter Meulen Fonds lecture: It is not all asthma that wheezes. 27e Congres Nederlandse Vereniging voor Kindergeneeskunde, Veldhoven (2005)

ESPID Fellowship Award 2001 Immunopathogenetic mechanisms of RSV infection in the mouse model (2001)

Royal Dutch Academy of Science (Ter Meulen Fonds Stipendium). Immunopathogenetic mechanisms of RSV infection in the mouse model (2000)

Research Output (253)

Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components:the PRIMA birth cohort

van Stigt Arthur H., Oude Rengerink Katrien, Bloemenkamp Kitty W.M., de Waal Wouter, Prevaes Sabine M.P.J., Le Thuy My, van Wijk Femke, Nederend Maaike, Hellinga Anneke H., Lammers Christianne S., den Hartog Gerco, van Herwijnen Martijn J.C., Garssen Johan, Knippels Léon M.J., Verhagen Lilly M., de Theije Caroline G.M., Lopez-Rincon Alejandro, Leusen Jeanette H.W., Van't Land Belinda, Bont Louis, 14 Feb 2022, In: BMC Infectious Diseases. 22

Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US

Zheng Zhe, Pitzer Virginia E, Shapiro Eugene D, Bont Louis J, Weinberger Daniel M 16 Dec 2021, In: JAMA network open. 4 , p. 1-13

COVID-19 Lesson for Respiratory Syncytial Virus (RSV):Hygiene Works

Gastaldi Andrea, Donà Daniele, Barbieri Elisa, Giaquinto Carlo, Bont Louis J, Baraldi Eugenio 6 Dec 2021, In: Children (Basel, Switzerland). 8 , p. 1-9

Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus

Lin Gu Lung, Drysdale Simon B., Snape Matthew D., O’Connor Daniel, Brown Anthony, MacIntyre-Cockett George, Mellado-Gomez Esther, de Cesare Mariateresa, Bonsall David, Ansari M. Azim, Öner Deniz, Aerssens Jeroen, Butler Christopher, Bont Louis, Openshaw Peter, Martinón-Torres Federico, Nair Harish, Bowden Rory, Campbell Harry, Cunningham Steve, Bogaert Debby, Beutels Philippe, Wildenbeest Joanne, Clutterbuck Elizabeth, McGinley Joseph, Thwaites Ryan, Wiseman Dexter, Gómez-Carballa Alberto, Rodriguez-Tenreiro Carmen, Rivero-Calle Irene, Dacosta-Urbieta Ana, Heikkinen Terho, Meijer Adam, Fischer Thea Kølsen, van den Berge Maarten, Giaquinto Carlo, Abram Michael, Dormitzer Philip, Stoszek Sonia, Gallichan Scott, Rosen Brian, Molero Eva, Machin Nuria, Spadetto Martina, Golubchik Tanya, Pollard Andrew J., Dec 2021, In: Nature Communications. 12 , p. 1-11 11 p.

Rotavirus Vaccine Safety and Effectiveness in Infants With High-Risk Medical Conditions

van Dongen Josephine A P, Rouers Elsbeth D M, Schuurman Rob, Band Caterina, Watkins Shannon M, van Houten Marlies A, Bont Louis J, Norbruis Obbe F, Hemels Marieke A C, van Well Gijs T J, Vlieger Arine M, van der Sluijs Jacqueline, Stas Helene G, Tramper-Stranders Gerdien, Kleinlugtenbeld Elly A, van Kempen Anne A M W, Wessels Margreet, van Rossem Maaike C, Dassel Carin A C M, Pajkrt Dasja, Bonten Marc J M, Bruijning-Verhagen Patricia C J 22 Nov 2021, In: Pediatrics. 148

RSV:perspectives to strengthen the need for protection in all infants

Navarro Alonso Jose Antonio, Bont Louis J., Bozzola Elena, Herting Egbert, Lega Federico, Mader Silke, Nunes Marta C., Ramilo Octavio, Valiotis George, Olivier Catherine Weil, Yates Ann, Faust Saul N. 21 Oct 2021, In: Emerging Themes in Epidemiology. 18 , p. 1-5

Publisher Correction::Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus

Lin Gu Lung, Drysdale Simon B., Snape Matthew D., O’Connor Daniel, Brown Anthony, MacIntyre-Cockett George, Mellado-Gomez Esther, de Cesare Mariateresa, Bonsall David, Ansari M. Azim, Öner Deniz, Aerssens Jeroen, Butler Christopher, Bont Louis, Openshaw Peter, Martinón-Torres Federico, Nair Harish, Bowden Rory, Campbell Harry, Cunningham Steve, Bogaert Debby, Beutels Philippe, Wildenbeest Joanne, Clutterbuck Elizabeth, McGinley Joseph, Thwaites Ryan, Wiseman Dexter, Gómez-Carballa Alberto, Rodriguez-Tenreiro Carmen, Rivero-Calle Irene, Dacosta-Urbieta Ana, Heikkinen Terho, Meijer Adam, Fischer Thea Kølsen, van den Berge Maarten, Giaquinto Carlo, Abram Michael, Dormitzer Philip, Stoszek Sonia, Gallichan Scott, Rosen Brian, Molero Eva, Machin Nuria, Spadetto Martina, Golubchik Tanya, Pollard Andrew J., 7 Oct 2021, In: Nature Communications. 12 , p. 1

Are changes in practice a cause of the rising burden of bronchiolitis for paediatric intensive care units?

Linssen Rosalie S., van Woensel Job B.M., Bont Louis, Recher Morgan, Campbell Harry, Ralston Shawn L., Bem Reinout A. Oct 2021, In: The Lancet Respiratory Medicine. 9 , p. 1094-1096 3 p.

Global Respiratory Syncytial Virus-Related Infant Community Deaths

Mazur Natalie I, Löwensteyn Yvette N, Willemsen Joukje E, Gill Christopher J, Forman Leah, Mwananyanda Lawrence M, Blau Dianna M, Breiman Robert F, Madhi Shabir A, Mahtab Sana, Gurley Emily S, El Arifeen Shams, Assefa Nega, Scott J Anthony G, Onyango Dickens, Tippet Barr Beth A, Kotloff Karen L, Sow Samba O, Mandomando Inacio, Ogbuanu Ikechukwu, Jambai Amara, Bassat Quique, Caballero Mauricio T, Polack Fernando P, Omer Saad, Kazi Abdul Momin, Simões Eric A F, Satav Ashish, Bont Louis J, 1 Sep 2021, In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73 , p. S229-S237

Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics:the RSV GOLD-III study protocol

Löwensteyn Yvette N, Mazur Natalie I, Nair Harish, Willemsen Joukje E, van Thiel Ghislaine, Bont Louis, 23 Aug 2021, In: BMC Infectious Diseases. 21

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet